I recently had the opportunity to review Eli Lilly's gene therapy pipeline while scoping a project for work. They had some billion-dollar acquisitions (Verve (LNP, Prevail (AAV)), and it looks like they are collecting the building blocks for gene therapy and successful delivery platforms; a big signal for this field. Worth adding to your table.
I work in clinical development and trials for gene therapy are fascinating!
One of the best breakdowns on this topic that I've come across. Would love one on the selection factors for cargo (e.g. gene therapy vs. editing vs. ASO, etc.)!
Thanks for this write-up!
I recently had the opportunity to review Eli Lilly's gene therapy pipeline while scoping a project for work. They had some billion-dollar acquisitions (Verve (LNP, Prevail (AAV)), and it looks like they are collecting the building blocks for gene therapy and successful delivery platforms; a big signal for this field. Worth adding to your table.
I work in clinical development and trials for gene therapy are fascinating!
One of the best breakdowns on this topic that I've come across. Would love one on the selection factors for cargo (e.g. gene therapy vs. editing vs. ASO, etc.)!
Entos Pharmaceuticals is doing groundbreaking work on expanding the capabilities of LNPs. Really revolutionary. https://entospharma.com/